Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making
Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making
批准号:
10797946
负责人:
AL B BENSON
金额:
$222.45万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-01 至 2026-08-31
中文摘要
项目总结
更详细地了解癌症新疗法的安全性和有效性的基本原理是
令人信服。虽然癌症治疗总是对健康和健康质量都有一定的风险
生活,在过去的十年里,治疗学发生了很大的变化。最重要的是,更好地理解
癌症的生物学特征导致了对人群的更细微的定义,这些人群可能比
以前都是可能的。随着基因组学的更多使用和由此产生的精确分子的规范
靶肿瘤的特征,以及通过(虽然早期)敏感性和抗药性的标记
免疫疗法,无论是适应症还是新疗法的使用都导致了更高的应答率
成功率和更有利的结果,至少从临床试验的进展来看是这样。平行推进的
医疗保健和普遍采用电子健康记录(EHR),同时质量有所提高
生活质量(QOL)和其他患者报告的结果(PRO),使更深入地分析
新疗法的效果和风险,因为它们的使用在整个医疗系统中扩散。紧随其后
关于鼓励和定义使用真实世界数据(RWD)以提供真实世界数据的效果的几点指导意见
世界证据(RWE),这一资助机制旨在促进捕获、组织和
分析RWD以生产RWE。我们在这里提出一种多管齐下的方法,将两种方法结合在一起
战略:1)重新设想如何获得稳健、有代表性和准确的RWD
来自现有临床试验的过程;2)有效的RWD方法如何在罕见的情况下产生强大的RWE
和不太常见的肿瘤相似。为了帮助实现这一目标,我们与Optom Life建立了合作关系
科学,既是为了帮助招募具有特定分子特征的不同群体,也是为了表征
在不同领域拥有扩展数据库的人口。我们的目标是第一,协调第三阶段和
第四阶段对新疗法的评估,以获得第三阶段标准疗法的真实证据;以及
随后在第四阶段成功治疗;第二,利用这种合作小组模式,建立
评估罕见肿瘤新疗法的真实世界数据第四阶段方法的可行性。我们
希望通过开发这些方法在短时间内收集严格的数据,我们将
作为对并行开发的数据收集的信息学方法的补充,并为它们提供
强大的数据库,用于比较分析。
英文摘要
PROJECT SUMMARY
The rationale for a more detailed understanding of the safety and efficacy of new therapies for cancer is
compelling. While cancer therapies have always had an element of risk to both well-being and to quality of
life, much has changed in therapeutics in the past ten years. Most important, a greater understanding of the
biological characteristics of cancer has led to more nuanced definitions of populations that may benefit than
were previously possible. With greater use of genomics and resulting specification of precise molecular
characteristics of target cancers, and through (though early) markers of sensitivity and resistance to
immunotherapeutics, both the indications and the use of novel therapeutics is resulting in higher response
rates and more favorable outcomes, at least as judged by progress in clinical trials. Parallel advances in
medical care and the universal adoption of an electronic health record (EHR), coupled with advances in quality
of life (QOL) and other patient-reported outcomes (PROs), have made possible a deeper analysis of the
effects and the risks of new therapies as their use is diffused throughout the medical system. Following upon
several guidances to the effect of encouraging and defining the use of real-world data (RWD) to provide real-
world evidence (RWE), this funding mechanism is designed to foster approaches to capture, organize, and
analyze RWD to produce RWE. We propose herein a many-pronged approach that brings together two
strategies: 1) a reimagining of how acquisition of robust, representative, and accurate RWD could be obtained
from existing clinical trials' processes; 2) how an effective RWD approach could generate robust RWE in rare
and less common tumors alike. To assist in this goal, we have developed a collaboration with Optum Life
Sciences, both to help recruit diverse populations with specific molecular profiles, and to characterize
populations with extended databases in various domains. Our Aims are first, to harmonize Phase III and
Phase IV evaluations of new therapies to obtain real-world evidence of the standard therapy in Phase III, and
subsequently of the successful therapy in Phase IV; second, using this cooperative group model, to establish
feasibility of a real-world data Phase IV approach to the evaluation of new therapies for rare tumors. We
expect that by developing these approaches to rigorous data collection in a short timeframe, we will be
complementary to informatics approaches to data collection developed in parallel and provide for them a
robust database for comparative analyses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Northwestern University Lead Academic Participating Site, GY4 Supplemental Request
-
批准号:10736415
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2022
-
负责人:AL B BENSON
-
依托单位:
Northwestern University Lead Academic Participating Site
-
批准号:10357915
-
项目类别:
-
资助金额:$51.52万
-
财政年份:2019
-
负责人:AL B BENSON
-
依托单位:
Northwestern University Lead Academic Participating Site
-
批准号:10583453
-
项目类别:
-
资助金额:$77.52万
-
财政年份:2019
-
负责人:AL B BENSON
-
依托单位:
Northwestern University Lead Academic Participating Site
-
批准号:9901493
-
项目类别:
-
资助金额:$51.52万
-
财政年份:2019
-
负责人:AL B BENSON
-
依托单位:
Northwestern University Lead Academic Participating Site Supplement Year 2
-
批准号:10299729
-
项目类别:
-
资助金额:$31.5万
-
财政年份:2019
-
负责人:AL B BENSON
-
依托单位:
Northwestern University Lead Academic Participating Site
-
批准号:10062109
-
项目类别:
-
资助金额:$17.5万
-
财政年份:2019
-
负责人:AL B BENSON
-
依托单位:
NU 98X3: IRINOTECAN (CPT-11) AND GEMCITABINE IN PATIENTS WITH SOLID TUMORS
-
批准号:7604237
-
项目类别:
-
资助金额:$0.59万
-
财政年份:2006
-
负责人:AL B BENSON
-
依托单位:
NU 98X3: IRINOTECAN (CPT-11) AND GEMCITABINE IN PATIENTS WITH SOLID TUMORS
-
批准号:7200422
-
项目类别:
-
资助金额:$0.41万
-
财政年份:2004
-
负责人:AL B BENSON
-
依托单位:
NU 98X3: Irinotecan (CPT-11) and Gemcitabine in Patients with Solid Tumors
-
批准号:7040344
-
项目类别:
-
资助金额:$0.59万
-
财政年份:2003
-
负责人:AL B BENSON
-
依托单位:
CORE--CLINICAL RESEARCH OFFICE
-
批准号:6396860
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1999
-
负责人:AL B BENSON
-
依托单位:
CORE--CLINICAL RESEARCH OFFICE
-
批准号:6395751
-
项目类别:
-
资助金额:$0.13万
-
财政年份:1999
-
负责人:AL B BENSON
-
依托单位:
CORE--CLINICAL RESEARCH OFFICE
-
批准号:6269629
-
项目类别:
-
资助金额:$14.0万
-
财政年份:1998
-
负责人:AL B BENSON
-
依托单位:
CORE--CLINICAL RESEARCH OFFICE
-
批准号:6102938
-
项目类别:
-
资助金额:$0.13万
-
财政年份:1998
-
负责人:AL B BENSON
-
依托单位:
Protocol Review and Monitoring System
-
批准号:10902202
-
项目类别:
-
资助金额:$17.2万
-
财政年份:1997
-
负责人:AL B BENSON
-
依托单位:
Protocol Review and Monitoring System
-
批准号:10228213
-
项目类别:
-
资助金额:$23.44万
-
财政年份:1997
-
负责人:AL B BENSON
-
依托单位:
Protocol Review and Monitoring System
-
批准号:10460220
-
项目类别:
-
资助金额:$23.44万
-
财政年份:1997
-
负责人:AL B BENSON
-
依托单位:
CORE--CLINICAL RESEARCH OFFICE
-
批准号:6237432
-
项目类别:
-
资助金额:$13.33万
-
财政年份:1997
-
负责人:AL B BENSON
-
依托单位:
THYMIDYLATE SYNTHASE EXPRESSION IN COLORECTAL CANCER
-
批准号:2110756
-
项目类别:
-
资助金额:$15.34万
-
财政年份:1995
-
负责人:AL B BENSON
-
依托单位:
THYMIDYLATE SYNTHASE EXPRESSION IN COLORECTAL CANCER
-
批准号:2110757
-
项目类别:
-
资助金额:$15.74万
-
财政年份:1995
-
负责人:AL B BENSON
-
依托单位:
PHASE I AND PHARMACOKINETIC STUDIES OF OLTIPRAZ
-
批准号:3622066
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1989
-
负责人:AL B BENSON
-
依托单位:
国内基金
海外基金
国际心脏研究会第二十三届世界大会(XXIII World Congress ISHR)
-
批准号:81942001
-
项目类别:专项基金项目
-
资助金额:10万元
-
批准年份:2019
-
负责人:朱毅
-
依托单位: